ClinicalTrials.gg
CompletedNCT00460603Updated Dec 6, 2013Results posted

Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer

A Phase 1/2 interventional study of bevacizumab and AG-013726 in Colorectal Neoplasms, sponsored by Pfizer. Completed at 107 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-06.

Sponsored by Pfizer · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
187
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies in Colorectal Neoplasms by Pfizer — 6 open to participants now, 14 under way, 3 of them phase 3. Colorectal Neoplasms · Pfizer.

Enrollment
15th of 68
187 · median 72
Started
2006
with 1 other
Phase 1/2
6 of 73
none open now
Registered
14th of 73
by date

Among the 73 studies in Colorectal Neoplasms by Pfizer, this one is the 15th largest by enrollment of the 68 interventional ones that give a count, is one of 2 that started in 2006, is one of 6 in phase 1/2, and was the 14th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

6 of the 73 studies in Colorectal Neoplasms by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Colorectal Neoplasms by Pfizer, or all of them as a file.
02

Study summary

To determine the safety and efficacy of AG-013736 in combination with other standard of care medication in patients with first line metastatic colorectal cancer.

03

Conditions studied

  • Colorectal Neoplasms

Keywords

  • GI neoplasms (phase 1)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (Phase 1) Patients with any solid/GI tumor who have had no more than 1 previous chemotherapy for greater than 3 months prior to enrollment
  • (Phase 2) Patients with locally advanced or colorectal cancer (CRC) previously untreated with any systemic therapy.
  • Patients treated with chemotherapy (with radiation) will be eligible if last treatment was > 12 months prior to enrollment,
  • Patients must have by and if any history of hypertension, it must be controlled with medication.

Exclusion criteria

Exclusion Criteria:

  • Prior system therapy for advanced CRC (Ph 2 portion only)
  • Prior treatment with anti-angiogenesis agent such as bevacizumab or VEGF inhibitors.
  • Prior irradiation of greater than 25% of bone marrow (whole pelvis = 25%)
  • Prior radiation, major surgery, or agent within 4 weeks of study entry except palliative radiotherapy to non-target, lesions. Minor surgeries should be completed > 2 weeks of enrollment and be fully recovered from any procedure.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
187 participants (actual)

Study arms

  • Active comparator
    B

    bevacizumab 5 mg/kg every 2 weeks + FOLFOX

    Drug: bevacizumab

  • Experimental
    C

    AG-013726 5 mg bid+ bevacizumab 2 mg/kg every 2 weeks + FOLFOX

    Drug: AG-013726

  • Experimental
    A

    AG-013736 5 mg bid starting dose + FOLFOX

    Drug: AG-013736 (axitinib)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Objective Response: Phase 2

    Percentage of participants with objective response (OR) based assessment of confirmed complete response(CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed CR defined as disappearance of all lesions and no appearance of new lesions. Confirmed PR defined as \>=30 percent (%) decrease in sum of the longest dimensions (LD) of the target lesions taking as reference the baseline sum LD , without progression of nontarget lesions and no appearance of new lesions. Confirmed responses are those that persist on repeat imaging study \>=4 weeks after initial documentation of response.

    Time frame: Baseline (Phase 2) until disease progression, assessed every 6 weeks up to Week 148 (Phase 2) or follow-up (every 6 weeks after last dose of study drug until progression or start of alternate therapy)

Secondary outcomes

  1. Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Axitinib: Phase 1

    Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). Pharmacokinetic (PK) parameters of axitinib (AG-013736) were combined for Cohorts 1, 2, and 3. AUClast for axitinib in absence of bevacizumab + FOLFOX was estimated from Cycle 1 Day 8 data and in presence of bevacizumab + FOLFOX was estimated from Cycle 2 Day 1 data. Results were normalized to axitinib 5 mg dose.

    Time frame: Predose, 1, 2, 2.5, 4, 6 and 8 hours postdose on Cycle 1 Day 8, Cycle 2 Day 1

  2. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] For Axitinib: Phase 1

    AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It was obtained from AUC (0 - t) plus AUC (t - ∞). PK parameters of axitinib (AG-013736) were combined for Cohorts 1, 2, and 3. AUC (t - ∞\] for axitinib in absence of bevacizumab + FOLFOX was estimated from Cycle 1 Day 8 data and in presence of bevacizumab + FOLFOX was estimated from Cycle 2 Day 1 data. Results were normalized to axitinib 5 mg dose.

    Time frame: Predose, 1, 2, 2.5, 4, 6, 8 hours postdose on Cycle 1 Day 8, Cycle 2 Day 1

  3. Maximum Observed Plasma Concentration (Cmax) For Axitinib: Phase 1

    PK parameters of axitinib (AG-013736) were combined for Cohorts 1, 2, and 3.Cmax for axitinib (AG-013736) in absence of bevacizumab + FOLFOX was estimated from Cycle 1 Day 8 data and in presence of bevacizumab + FOLFOX was estimated from Cycle 2 Day 1 data. Results were normalized to axitinib 5 mg dose.

    Time frame: Predose, 1, 2, 2.5, 4, 6, 8 hours postdose on Cycle 1 Day 8, Cycle 2 Day 1

  4. Minimum Observed Plasma Trough Concentration (Cmin) For Axitinib: Phase 1

    Time frame: Predose, 1, 2, 2.5, 4, 6, 8 hours postdose on Cycle 1 Day 8, Cycle 2 Day 1

  5. Apparent Oral Clearance (CL/F) For Axitinib: Phase 1

    Clearance (CL) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed (F). Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. PK parameters of axitinib (AG-013736) were combined for Cohorts 1, 2, and 3. CL/F for axitinib (AG-013736) in absence of bevacizumab + FOLFOX was estimated from Cycle 1 Day 8 data and in presence of bevacizumab + FOLFOX was estimated from Cycle 2 Day 1 data.

    Time frame: Predose, 1, 2, 2.5, 4, 6, 8 hours postdose on Cycle 1 Day 8, Cycle 2 Day 1

  6. Plasma Decay Half-Life (t1/2) For Axitinib: Phase 1

    Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half. PK parameters of axitinib (AG-013736) were combined for Cohorts 1, 2, and 3. t1/2 for axitinib in absence of bevacizumab + FOLFOX was estimated from Cycle 1 Day 8 data and in presence of bevacizumab + FOLFOX was estimated from Cycle 2 Day 1 data.

    Time frame: Predose, 1, 2, 2.5, 4, 6, 8 hours postdose on Cycle 1 Day 8, Cycle 2 Day 1

  7. Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Oxaliplatin: Phase 1

    Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). PK parameters of oxaliplatin, assessed by estimating total platinum in plasma ultrafiltrate, were combined for Cohorts 1, 2, and 3. AUClast for oxaliplatin in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 oxaliplatin dose.

    Time frame: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

  8. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] For Oxaliplatin: Phase 1

    AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It was obtained from AUC (0 - t) plus AUC (t - ∞). PK parameters of oxaliplatin, assessed by estimating total platinum in plasma ultrafiltrate, were combined for Cohorts 1, 2, and 3. AUC (0 - ∞) for oxaliplatin in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 oxaliplatin dose.

    Time frame: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

  9. Maximum Observed Plasma Concentration (Cmax) For Oxaliplatin: Phase 1

    PK parameters of oxaliplatin, assessed by estimating total platinum in plasma ultrafiltrate, were combined for Cohorts 1, 2, and 3. Cmax for oxaliplatin in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 oxaliplatin dose.

    Time frame: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

  10. Minimum Observed Plasma Trough Concentration (Cmin) For Oxaliplatin: Phase 1

    Time frame: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

  11. Clearance (CL) For Oxaliplatin: Phase 1

    CL is a quantitative measure of the rate at which a drug substance is removed from the body. PK parameters of oxaliplatin, assessed by estimating total platinum in plasma ultrafiltrate, were combined for Cohorts 1, 2, and 3. CL for oxaliplatin in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data.

    Time frame: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

  12. Plasma Decay Half-Life (t1/2) For Oxaliplatin: Phase 1

    Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half. PK parameters of oxaliplatin, assessed by estimating total platinum in plasma ultrafiltrate, were combined for Cohorts 1, 2, and 3. t1/2 for oxaliplatin in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data.

    Time frame: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

  13. Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For 5-Fluorouracil: Phase 1

    Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). PK parameters of 5-FU were combined for Cohorts 1, 2, and 3. AUClast for 5-FU in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 5-FU dose.

    Time frame: Pre-5-FU bolus, 5 min (post-5-FU bolus), 0.25, 0.5, 0.75, 2, 4, 6, 22, 34-46 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

  14. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] For 5-Fluorouracil: Phase 1

    AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It was obtained from AUC (0 - t) plus AUC (t - ∞). PK parameters of 5-FU were combined for Cohorts 1, 2, and 3. AUC (0 - ∞) for 5-FU in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 5-FU dose.

    Time frame: Pre-5-FU bolus, 5 min (post-5-FU bolus), 0.25, 0.5, 0.75, 2, 4, 6, 22, 34-46 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

  15. Maximum Observed Plasma Concentration (Cmax) For 5-Fluorouracil: Phase 1

    PK parameters of 5-FU were combined for Cohorts 1, 2, and 3. Cmax for 5-FU in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 5-FU dose.

    Time frame: Pre-5-FU bolus, 5 min (post-5-FU bolus), 0.25, 0.5, 0.75, 2, 4, 6, 22, 34-46 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

  16. Minimum Observed Plasma Trough Concentration (Cmin) For 5-Fluorouracil: Phase 1

    Time frame: Pre-5-FU bolus, 5 min (post-5-FU bolus), 0.25, 0.5, 0.75, 2, 4, 6, 22, 34-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

  17. Clearance (CL) For 5-Fluorouracil: Phase 1

    CL is a quantitative measure of the rate at which a drug substance is removed from the body. PK parameters of 5-FU were combined for Cohorts 1, 2, and 3. CL for 5-FU in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data.

    Time frame: Pre-5-FU bolus, 5 min (post-5-FU bolus), 0.25, 0.5, 0.75, 2, 4, 6, 22, 34-46 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

  18. Plasma Decay Half-Life (t1/2) For 5-Fluorouracil: Phase 1

    Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half. PK parameters of 5-FU were combined for Cohorts 1, 2, and 3. t1/2 for 5-FU in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data.

    Time frame: Pre-5-FU bolus, 5 min (post-5-FU bolus), 0.25, 0.5, 0.75, 2, 4, 6, 22, 34-46 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

  19. Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Irinotecan: Phase 1

    Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). AUClast for irinotecan in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 irinotecan dose.

    Time frame: Predose, 1, 2, 2.5, 4, 6, 8, 24 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

  20. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] For Irinotecan: Phase 1

    AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It was obtained from AUC (0 - t) plus AUC (t - ∞). AUC (0 - ∞) for irinotecan in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 irinotecan dose.

    Time frame: Predose, 1, 2, 2.5, 4, 6, 8, 24 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

  21. Maximum Observed Plasma Concentration (Cmax) For Irinotecan: Phase 1

    Cmax for irinotecan in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 irinotecan dose.

    Time frame: Predose, 1, 2, 2.5, 4, 6, 8, 24 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

  22. Minimum Observed Plasma Trough Concentration (Cmin) For Irinotecan: Phase 1

    Time frame: Predose, 1, 2, 2.5, 4, 6, 8, 24 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

  23. Clearance (CL) For Irinotecan: Phase 1

    CL is a quantitative measure of the rate at which a drug substance is removed from the body. CL for irinotecan in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data.

    Time frame: Predose, 1, 2, 2.5, 4, 6, 8, 24 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

  24. Plasma Decay Half-Life (t1/2) For Irinotecan: Phase 1

    Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half. t1/2 for irinotecan in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data.

    Time frame: Predose, 1, 2, 2.5, 4, 6, 8, 24 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

  25. Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Bevacizumab: Phase 1

    Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). PK parameters of bevacizumab were combined for Cohorts 1, 2, and 3. AUClast for bevacizumab in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. The bevacizumab pharmacokinetic parameters were normalized to 1 mg/kg dose.

    Time frame: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

  26. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] For Bevacizumab: Phase 1

    AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It was obtained from AUC (0 - t) plus AUC (t - ∞). PK parameters of bevacizumab were combined for Cohorts 1, 2, and 3. AUC (0 - ∞) for bevacizumab in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. The bevacizumab pharmacokinetic parameters were normalized to 1 mg/kg dose.

    Time frame: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

  27. Maximum Observed Plasma Concentration (Cmax) For Bevacizumab: Phase 1

    PK parameters of bevacizumab were combined for Cohorts 1, 2, and 3. Cmax for bevacizumab in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. The bevacizumab pharmacokinetic parameters were normalized to 1 mg/kg dose.

    Time frame: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

  28. Minimum Observed Plasma Trough Concentration (Cmin) For Bevacizumab: Phase 1

    Time frame: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

  29. Clearance (CL) For Bevacizumab: Phase 1

    CL is a quantitative measure of the rate at which a drug substance is removed from the body. PK parameters of bevacizumab were combined for Cohorts 1, 2, and 3. CL for bevacizumab in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data.

    Time frame: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

  30. Plasma Decay Half-Life (t1/2) For Bevacizumab: Phase 1

    Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half. PK parameters of bevacizumab were combined for Cohorts 1, 2, and 3. t1/2 for bevacizumab in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data.

    Time frame: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

  31. Duration of Response (DR): Phase 2

    Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response. CR: disappearance of all lesions and no appearance of new lesions. PR: \>=30% decrease in sum of LD of target lesions taking as reference the baseline sum LD, without progression of nontarget lesions and no appearance of new lesions. Progression: \>=20% increase in sum of LD of target lesions taking as references the smallest sum LD recorded since treatment start, unequivocal progression of existing nontarget lesions, or appearance of new lesions, occurrence of pleural effusion/ascites, substantiated by cytologic investigation.

    Time frame: Baseline (Phase 2) until disease progression, assessed every 6 weeks up to Week 148 (Phase 2) or follow-up (every 6 weeks after last dose of study drug until progression or start of alternate therapy)

  32. Progression-Free Survival (PFS): Phase 2

    Time in days from date of randomization to first documentation of objective tumor progression or death due to any cause. PFS was calculated as first event date minus the date of first dose of study medication plus 1. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death"). Progression: \>=20% increase in sum of LD of target lesions taking as references the smallest sum LD recorded since treatment start, unequivocal progression of existing nontarget lesions, or appearance of new lesions, occurrence of pleural effusion/ascites, substantiated by cytologic investigation.

    Time frame: Baseline (Phase 2) until disease progression, assessed every 6 weeks up to Week 148 (Phase 2) or follow-up (every 6 weeks after last dose of study drug until progression or start of alternate therapy)

  33. Time to Treatment Failure (TTF): Phase 2

    TTF is defined as the time from the randomization to the date of the first documentation of PD, symptomatic deterioration, death due to any cause, or treatment discontinuation due to adverse event, refusal or other reasons. Progression: \>=20% increase in sum of LD of target lesions taking as references the smallest sum LD recorded since treatment start, unequivocal progression of existing nontarget lesions, or appearance of new lesions, occurrence of pleural effusion/ascites, substantiated by cytologic investigation.

    Time frame: Baseline (Phase 2) until disease progression, assessed every 6 weeks up to Week 148 (Phase 2) or follow-up (every 6 weeks after last dose of study drug until progression or start of alternate therapy)

  34. Overall Survival (OS): Phase 2

    Time in days from randomization date to date of death due to any cause. OS was calculated as the death date minus the date of first dose of study medication plus 1. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).

    Time frame: Every 3 months after discontinuation of study treatment until death due to any cause or 1 year after randomization of the last participant

  35. Change From Baseline in M.D. Anderson Symptom Assessment Inventory - Diarrhea (MDASI-D) Symptom Severity and Interference Subscale Scores at Day 1 of Cycle 2 Through Day 1 Cycle 42 and Follow-up: Phase 2

    PROs included assessment of symptom severity and interference which were measured using M.D. Anderson Symptom Assessment Inventory-Diarrhea (MDASI-D), 20-item questionnaire which assesses the severity of 14 symptoms over the past 24 hours, as well as symptoms interference with 6 areas of function (e.g., walking, work, mood), when the symptom was "at its worst". Each item is scored from 0 to 10, with '0' indicating that the symptom was either not present or did not interfere with their activities, and '10' indicating that the symptom was "as bad as you can imagine" or "interfered completely" with their life. The 2 subscales, symptom severity score and symptom interference score were average of respective items and ranged from 0 to 10, higher score indicating greater severity or interference of symptoms.

    Time frame: Cycle 1 Day 1 (baseline), every 2 weeks for the first 2 months (Cycle 2 Day 1 [C2D1], Cycle 3 Day 1, and Cycle 4 Day 1) then monthly thereafter starting Cycle 6 Day 1, and 28 days after the last dose

07

Results

Posted Jun 4, 2013
Limitations and caveats
Time to Treatment Failure (TTF) was included as a secondary endpoint of the study after change in analysis plan.

Participant flow

Phase 1
Participant flow — Phase 1
MilestonePhase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1)Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 2)Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 3)Phase 1: Axitinib + FOLFIRI (Cohort 4)Phase 1: Axitinib + FOLFOX (Cohort 5)Phase 1: Axitinib + FOLFIRI (Cohort 6)Phase 1: Axitinib + FOLFOX (Cohort 7)Phase 1: Axitinib + FOLFIRI (Cohort 8)Phase 1: Axitinib + FOLFIRI (Cohort 9)Phase 2: Axitinib + FOLFOXPhase 2: Bevacizumab + FOLFOXPhase 2: Axitinib + Bevacizumab + FOLFOX
Started6648646318000
Completed000000000000
Not completed6648646318000
Withdrew: Death100200001000
Withdrew: Adverse event311200304000
Withdrew: Lack of efficacy1012222211000
Withdrew: Withdrawal by subject121130102000
Withdrew: Other031112010000
Phase 2
Participant flow — Phase 2
MilestonePhase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1)Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 2)Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 3)Phase 1: Axitinib + FOLFIRI (Cohort 4)Phase 1: Axitinib + FOLFOX (Cohort 5)Phase 1: Axitinib + FOLFIRI (Cohort 6)Phase 1: Axitinib + FOLFOX (Cohort 7)Phase 1: Axitinib + FOLFIRI (Cohort 8)Phase 1: Axitinib + FOLFIRI (Cohort 9)Phase 2: Axitinib + FOLFOXPhase 2: Bevacizumab + FOLFOXPhase 2: Axitinib + Bevacizumab + FOLFOX
Started000000000424341
Treated000000000394341
Completed000000000000
Not completed000000000424341
Withdrew: Ongoing in study a4061008 (nct00828919)000000000100
Withdrew: Adverse event00000000012910
Withdrew: Death000000000422
Withdrew: Protocol violation000000000110
Withdrew: Lost to follow-up000000000100
Withdrew: Other0000000006167
Withdrew: Objective progression or relapse00000000091017
Withdrew: Global deterioration of health status000000000010
Withdrew: Withdrawal by subject000000000545
Withdrew: Randomized, but not treated000000000300

Outcome measures

PrimaryPercentage of Participants With Objective Response: Phase 2

Percentage of participants with objective response (OR) based assessment of confirmed complete response(CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed CR defined as disappearance of all lesions and no appearance of new lesions. Confirmed PR defined as \>=30 percent (%) decrease in sum of the longest dimensions (LD) of the target lesions taking as reference the baseline sum LD , without progression of nontarget lesions and no appearance of new lesions. Confirmed responses are those that persist on repeat imaging study \>=4 weeks after initial documentation of response.

Time frame:
Baseline (Phase 2) until disease progression, assessed every 6 weeks up to Week 148 (Phase 2) or follow-up (every 6 weeks after last dose of study drug until progression or start of alternate therapy)
Reported as:
Number · Percentage of participants
Percentage of Participants With Objective Response: Phase 2
Percentage of participantsPhase 2: Axitinib + FOLFOXPhase 2: Bevacizumab + FOLFOXPhase 2: Axitinib + Bevacizumab + FOLFOX
Percentage of Participants With Objective Response: Phase 228.6 (15.7 to 44.6)48.8 (33.3 to 64.5)39.0 (24.2 to 55.5)
Statistical analysis
  • Phase 2: Axitinib + FOLFOX vs Phase 2: Bevacizumab + FOLFOX · Cochran-Mantel-Haenszel · p = 0.9726 · Risk ratio (rr): 0.585 · 95% CI 0.332 to 1.031
  • Phase 2: Axitinib + FOLFOX vs Phase 2: Axitinib + Bevacizumab + FOLFOX · Cochran-Mantel-Haenszel · p = 0.8391 · Risk ratio (rr): 0.735 · 95% CI 0.399 to 1.352
  • Phase 2: Bevacizumab + FOLFOX vs Phase 2: Axitinib + Bevacizumab + FOLFOX · Cochran-Mantel-Haenszel · p = 0.8192 · Risk ratio (rr): 0.797 · 95% CI 0.489 to 1.299
SecondaryArea Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Axitinib: Phase 1

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). Pharmacokinetic (PK) parameters of axitinib (AG-013736) were combined for Cohorts 1, 2, and 3. AUClast for axitinib in absence of bevacizumab + FOLFOX was estimated from Cycle 1 Day 8 data and in presence of bevacizumab + FOLFOX was estimated from Cycle 2 Day 1 data. Results were normalized to axitinib 5 mg dose.

Time frame:
Predose, 1, 2, 2.5, 4, 6 and 8 hours postdose on Cycle 1 Day 8, Cycle 2 Day 1
Reported as:
Geometric mean · nanogram hour per milliliter (ng*hr/mL)
Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Axitinib: Phase 1
nanogram hour per milliliter (ng*hr/mL)Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)Phase 1: Axitinib + FOLFIRI (Cohort 4)Phase 1: Axitinib + FOLFOX (Cohort 5)
Cycle 1 Day 8119.02 (56.17 to 252.21)106.76 (27.27 to 417.89)97.05 (49.01 to 192.16)
Cycle 2 Day 195.70 (45.16 to 202.80)143.68 (36.70 to 562.43)117.47 (59.32 to 232.60)
SecondaryArea Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] For Axitinib: Phase 1

AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It was obtained from AUC (0 - t) plus AUC (t - ∞). PK parameters of axitinib (AG-013736) were combined for Cohorts 1, 2, and 3. AUC (t - ∞\] for axitinib in absence of bevacizumab + FOLFOX was estimated from Cycle 1 Day 8 data and in presence of bevacizumab + FOLFOX was estimated from Cycle 2 Day 1 data. Results were normalized to axitinib 5 mg dose.

Time frame:
Predose, 1, 2, 2.5, 4, 6, 8 hours postdose on Cycle 1 Day 8, Cycle 2 Day 1
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] For Axitinib: Phase 1
ng*hr/mLPhase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)Phase 1: Axitinib + FOLFIRI (Cohort 4)Phase 1: Axitinib + FOLFOX (Cohort 5)
Cycle 1 Day 8190.51 (77.99 to 465.35)113.20 (8.89 to 1442.19)205.41 (53.61 to 787.01)
Cycle 2 Day 1224.46 (91.89 to 548.29)168.07 (13.19 to 2141.15)178.46 (46.58 to 683.73)
SecondaryMaximum Observed Plasma Concentration (Cmax) For Axitinib: Phase 1

PK parameters of axitinib (AG-013736) were combined for Cohorts 1, 2, and 3.Cmax for axitinib (AG-013736) in absence of bevacizumab + FOLFOX was estimated from Cycle 1 Day 8 data and in presence of bevacizumab + FOLFOX was estimated from Cycle 2 Day 1 data. Results were normalized to axitinib 5 mg dose.

Time frame:
Predose, 1, 2, 2.5, 4, 6, 8 hours postdose on Cycle 1 Day 8, Cycle 2 Day 1
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) For Axitinib: Phase 1
ng/mLPhase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)Phase 1: Axitinib + FOLFIRI (Cohort 4)Phase 1: Axitinib + FOLFOX (Cohort 5)
Cycle 1 Day 835.57 (18.37 to 68.89)27.14 (7.40 to 99.49)24.23 (14.32 to 40.98)
Cycle 2 Day 127.51 (14.20 to 53.28)42.48 (11.59 to 155.73)32.62 (19.29 to 55.18)
SecondaryMinimum Observed Plasma Trough Concentration (Cmin) For Axitinib: Phase 1
Time frame:
Predose, 1, 2, 2.5, 4, 6, 8 hours postdose on Cycle 1 Day 8, Cycle 2 Day 1

No measurements were reported for this outcome.

SecondaryApparent Oral Clearance (CL/F) For Axitinib: Phase 1

Clearance (CL) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed (F). Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. PK parameters of axitinib (AG-013736) were combined for Cohorts 1, 2, and 3. CL/F for axitinib (AG-013736) in absence of bevacizumab + FOLFOX was estimated from Cycle 1 Day 8 data and in presence of bevacizumab + FOLFOX was estimated from Cycle 2 Day 1 data.

Time frame:
Predose, 1, 2, 2.5, 4, 6, 8 hours postdose on Cycle 1 Day 8, Cycle 2 Day 1
Reported as:
Geometric mean · Liter per hour (L/hr)
Apparent Oral Clearance (CL/F) For Axitinib: Phase 1
Liter per hour (L/hr)Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)Phase 1: Axitinib + FOLFIRI (Cohort 4)Phase 1: Axitinib + FOLFOX (Cohort 5)
Cycle 1 Day 830.01 (15.05 to 59.82)47.10 (3.72 to 596.29)28.49 (9.32 to 87.03)
Cycle 2 Day 130.08 (15.09 to 59.96)33.33 (2.63 to 421.92)28.90 (9.46 to 88.31)
SecondaryPlasma Decay Half-Life (t1/2) For Axitinib: Phase 1

Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half. PK parameters of axitinib (AG-013736) were combined for Cohorts 1, 2, and 3. t1/2 for axitinib in absence of bevacizumab + FOLFOX was estimated from Cycle 1 Day 8 data and in presence of bevacizumab + FOLFOX was estimated from Cycle 2 Day 1 data.

Time frame:
Predose, 1, 2, 2.5, 4, 6, 8 hours postdose on Cycle 1 Day 8, Cycle 2 Day 1
Reported as:
Mean · hours
Plasma Decay Half-Life (t1/2) For Axitinib: Phase 1
hoursPhase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)Phase 1: Axitinib + FOLFIRI (Cohort 4)Phase 1: Axitinib + FOLFOX (Cohort 5)
Cycle 1 Day 83.26 ± 3.9432.23 ± 0.7023.47 ± 2.820
Cycle 2 Day 16.12 ± 7.4503.09 ± 0.8891.73 ± 0.456
SecondaryArea Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Oxaliplatin: Phase 1

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). PK parameters of oxaliplatin, assessed by estimating total platinum in plasma ultrafiltrate, were combined for Cohorts 1, 2, and 3. AUClast for oxaliplatin in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 oxaliplatin dose.

Time frame:
Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Reported as:
Geometric mean · ng*hr/mL
Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Oxaliplatin: Phase 1
ng*hr/mLPhase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)Phase 1: Axitinib + FOLFOX (Cohort 5)
Cycle 1 Day 14814.87 (4079.46 to 5682.84)4308.71 (2822.77 to 6576.87)
Cycle 2 Day 15231.71 (4432.64 to 6174.83)5303.66 (3474.59 to 8095.57)
SecondaryArea Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] For Oxaliplatin: Phase 1

AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It was obtained from AUC (0 - t) plus AUC (t - ∞). PK parameters of oxaliplatin, assessed by estimating total platinum in plasma ultrafiltrate, were combined for Cohorts 1, 2, and 3. AUC (0 - ∞) for oxaliplatin in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 oxaliplatin dose.

Time frame:
Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] For Oxaliplatin: Phase 1
ng*hr/mLPhase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)Phase 1: Axitinib + FOLFOX (Cohort 5)
Cycle 1 Day 15955.70 (4615.41 to 7685.21)5137.31 (3296.14 to 8006.93)
Cycle 2 Day 16744.06 (5226.35 to 8702.50)6430.67 (4125.97 to 10022.74)
SecondaryMaximum Observed Plasma Concentration (Cmax) For Oxaliplatin: Phase 1

PK parameters of oxaliplatin, assessed by estimating total platinum in plasma ultrafiltrate, were combined for Cohorts 1, 2, and 3. Cmax for oxaliplatin in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 oxaliplatin dose.

Time frame:
Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) For Oxaliplatin: Phase 1
ng/mLPhase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)Phase 1: Axitinib + FOLFOX (Cohort 5)
Cycle 1 Day 1278.81 (201.38 to 386.03)265.05 (67.62 to 1038.93)
Cycle 2 Day 1318.99 (230.40 to 441.66)374.03 (95.42 to 1466.10)
SecondaryMinimum Observed Plasma Trough Concentration (Cmin) For Oxaliplatin: Phase 1
Time frame:
Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

No measurements were reported for this outcome.

SecondaryClearance (CL) For Oxaliplatin: Phase 1

CL is a quantitative measure of the rate at which a drug substance is removed from the body. PK parameters of oxaliplatin, assessed by estimating total platinum in plasma ultrafiltrate, were combined for Cohorts 1, 2, and 3. CL for oxaliplatin in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data.

Time frame:
Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Reported as:
Geometric mean · L/hr
Clearance (CL) For Oxaliplatin: Phase 1
L/hrPhase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)Phase 1: Axitinib + FOLFOX (Cohort 5)
Cycle 1 Day 127.51 (21.56 to 35.11)30.74 (18.48 to 51.13)
Cycle 2 Day 124.29 (19.04 to 31.00)24.56 (14.76 to 40.85)
SecondaryPlasma Decay Half-Life (t1/2) For Oxaliplatin: Phase 1

Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half. PK parameters of oxaliplatin, assessed by estimating total platinum in plasma ultrafiltrate, were combined for Cohorts 1, 2, and 3. t1/2 for oxaliplatin in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data.

Time frame:
Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Reported as:
Mean · hours
Plasma Decay Half-Life (t1/2) For Oxaliplatin: Phase 1
hoursPhase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)Phase 1: Axitinib + FOLFOX (Cohort 5)
Cycle 1 Day 120.63 ± 6.51318.38 ± 3.004
Cycle 2 Day 123.30 ± 14.97519.86 ± 4.110
SecondaryArea Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For 5-Fluorouracil: Phase 1

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). PK parameters of 5-FU were combined for Cohorts 1, 2, and 3. AUClast for 5-FU in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 5-FU dose.

Time frame:
Pre-5-FU bolus, 5 min (post-5-FU bolus), 0.25, 0.5, 0.75, 2, 4, 6, 22, 34-46 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Reported as:
Geometric mean · ng*hr/mL
Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For 5-Fluorouracil: Phase 1
ng*hr/mLPhase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)Phase 1: Axitinib + FOLFIRI (Cohort 4)Phase 1: Axitinib + FOLFOX (Cohort 5)
Cycle 1 Day 139212.03 (22388.50 to 68677.39)40955.29 (23831.07 to 70384.39)52164.28 (4725.16 to 575877.57)
Cycle 2 Day 145087.71 (25743.27 to 78968.27)36533.84 (21258.32 to 62785.83)95123.13 (8616.47 to 1050129.94)
SecondaryArea Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] For 5-Fluorouracil: Phase 1

AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It was obtained from AUC (0 - t) plus AUC (t - ∞). PK parameters of 5-FU were combined for Cohorts 1, 2, and 3. AUC (0 - ∞) for 5-FU in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 5-FU dose.

Time frame:
Pre-5-FU bolus, 5 min (post-5-FU bolus), 0.25, 0.5, 0.75, 2, 4, 6, 22, 34-46 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] For 5-Fluorouracil: Phase 1
ng*hr/mLPhase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)Phase 1: Axitinib + FOLFIRI (Cohort 4)Phase 1: Axitinib + FOLFOX (Cohort 5)
Cycle 1 Day 136314.14 (19623.50 to 67200.90)41460.50 (23968.34 to 71718.51)52430.15 (4751.38 to 578551.86)
Cycle 2 Day 138983.80 (21066.13 to 72141.23)36776.79 (21260.68 to 63616.60)96632.41 (8757.13 to 1066311.16)
SecondaryMaximum Observed Plasma Concentration (Cmax) For 5-Fluorouracil: Phase 1

PK parameters of 5-FU were combined for Cohorts 1, 2, and 3. Cmax for 5-FU in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 5-FU dose.

Time frame:
Pre-5-FU bolus, 5 min (post-5-FU bolus), 0.25, 0.5, 0.75, 2, 4, 6, 22, 34-46 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) For 5-Fluorouracil: Phase 1
ng/mLPhase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)Phase 1: Axitinib + FOLFIRI (Cohort 4)Phase 1: Axitinib + FOLFOX (Cohort 5)
Cycle 1 Day 116160.85 (6975.82 to 37439.78)34436.94 (22763.46 to 52096.78)19622.74 (2754.12 to 139809.41)
Cycle 2 Day 116249.77 (7014.20 to 37645.79)39730.46 (26262.58 to 60104.90)34180.87 (4797.41 to 243534.09)
SecondaryMinimum Observed Plasma Trough Concentration (Cmin) For 5-Fluorouracil: Phase 1
Time frame:
Pre-5-FU bolus, 5 min (post-5-FU bolus), 0.25, 0.5, 0.75, 2, 4, 6, 22, 34-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

No measurements were reported for this outcome.

SecondaryClearance (CL) For 5-Fluorouracil: Phase 1

CL is a quantitative measure of the rate at which a drug substance is removed from the body. PK parameters of 5-FU were combined for Cohorts 1, 2, and 3. CL for 5-FU in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data.

Time frame:
Pre-5-FU bolus, 5 min (post-5-FU bolus), 0.25, 0.5, 0.75, 2, 4, 6, 22, 34-46 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Reported as:
Geometric mean · L/hr
Clearance (CL) For 5-Fluorouracil: Phase 1
L/hrPhase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)Phase 1: Axitinib + FOLFIRI (Cohort 4)Phase 1: Axitinib + FOLFOX (Cohort 5)
Cycle 1 Day 1147.43 (77.38 to 280.93)128.28 (73.44 to 224.05)99.36 (10.18 to 969.40)
Cycle 2 Day 1137.34 (72.08 to 261.70)144.62 (82.80 to 252.59)53.92 (5.53 to 526.06)
SecondaryPlasma Decay Half-Life (t1/2) For 5-Fluorouracil: Phase 1

Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half. PK parameters of 5-FU were combined for Cohorts 1, 2, and 3. t1/2 for 5-FU in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data.

Time frame:
Pre-5-FU bolus, 5 min (post-5-FU bolus), 0.25, 0.5, 0.75, 2, 4, 6, 22, 34-46 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Reported as:
Mean · hours
Plasma Decay Half-Life (t1/2) For 5-Fluorouracil: Phase 1
hoursPhase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)Phase 1: Axitinib + FOLFIRI (Cohort 4)Phase 1: Axitinib + FOLFOX (Cohort 5)
Cycle 1 Day 10.26 ± 0.2180.19 ± 0.0690.39 ± 0.291
Cycle 2 Day 10.25 ± 0.1420.14 ± 0.0290.24 ± 0.131
SecondaryArea Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Irinotecan: Phase 1

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). AUClast for irinotecan in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 irinotecan dose.

Time frame:
Predose, 1, 2, 2.5, 4, 6, 8, 24 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Reported as:
Geometric mean · ng*hr/mL
Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Irinotecan: Phase 1
ng*hr/mLPhase 1: Axitinib + FOLFIRI (Cohort 4)
Cycle 1 Day 112081.58 (8805.17 to 16577.15)
Cycle 2 Day 111496.32 (8378.62 to 15774.11)
SecondaryArea Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] For Irinotecan: Phase 1

AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It was obtained from AUC (0 - t) plus AUC (t - ∞). AUC (0 - ∞) for irinotecan in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 irinotecan dose.

Time frame:
Predose, 1, 2, 2.5, 4, 6, 8, 24 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] For Irinotecan: Phase 1
ng*hr/mLPhase 1: Axitinib + FOLFIRI (Cohort 4)
Cycle 1 Day 113055.88 (9371.39 to 18188.96)
Cycle 2 Day 112459.89 (8943.60 to 17358.66)
SecondaryMaximum Observed Plasma Concentration (Cmax) For Irinotecan: Phase 1

Cmax for irinotecan in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 irinotecan dose.

Time frame:
Predose, 1, 2, 2.5, 4, 6, 8, 24 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) For Irinotecan: Phase 1
ng/mLPhase 1: Axitinib + FOLFIRI (Cohort 4)
Cycle 1 Day 11910.25 (1561.45 to 2336.97)
Cycle 2 Day 11788.69 (1462.08 to 2188.26)
SecondaryMinimum Observed Plasma Trough Concentration (Cmin) For Irinotecan: Phase 1
Time frame:
Predose, 1, 2, 2.5, 4, 6, 8, 24 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

No measurements were reported for this outcome.

SecondaryClearance (CL) For Irinotecan: Phase 1

CL is a quantitative measure of the rate at which a drug substance is removed from the body. CL for irinotecan in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data.

Time frame:
Predose, 1, 2, 2.5, 4, 6, 8, 24 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Reported as:
Geometric mean · L/hr
Clearance (CL) For Irinotecan: Phase 1
L/hrPhase 1: Axitinib + FOLFIRI (Cohort 4)
Cycle 1 Day 826.09 (18.10 to 37.61)
Cycle 2 Day 127.34 (18.97 to 39.40)
SecondaryPlasma Decay Half-Life (t1/2) For Irinotecan: Phase 1

Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half. t1/2 for irinotecan in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data.

Time frame:
Predose, 1, 2, 2.5, 4, 6, 8, 24 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Reported as:
Mean · hours
Plasma Decay Half-Life (t1/2) For Irinotecan: Phase 1
hoursPhase 1: Axitinib + FOLFIRI (Cohort 4)
Cycle 1 Day 16.45 ± 1.406
Cycle 2 Day 16.75 ± 0.886
SecondaryArea Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Bevacizumab: Phase 1

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). PK parameters of bevacizumab were combined for Cohorts 1, 2, and 3. AUClast for bevacizumab in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. The bevacizumab pharmacokinetic parameters were normalized to 1 mg/kg dose.

Time frame:
Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Reported as:
Geometric mean · ng*hr/mL
Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Bevacizumab: Phase 1
ng*hr/mLPhase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)
Cycle 1 Day 13394758.83 (2453600.72 to 4696928.65)
Cycle 2 Day 13554899.52 (2569344.23 to 4918496.49)
SecondaryArea Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] For Bevacizumab: Phase 1

AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It was obtained from AUC (0 - t) plus AUC (t - ∞). PK parameters of bevacizumab were combined for Cohorts 1, 2, and 3. AUC (0 - ∞) for bevacizumab in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. The bevacizumab pharmacokinetic parameters were normalized to 1 mg/kg dose.

Time frame:
Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] For Bevacizumab: Phase 1
ng*hr/mLPhase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)
Cycle 1 Day 14987528.96 (3395240.62 to 7326563.24)
Cycle 2 Day 15114888.84 (3481940.36 to 7513651.92)
SecondaryMaximum Observed Plasma Concentration (Cmax) For Bevacizumab: Phase 1

PK parameters of bevacizumab were combined for Cohorts 1, 2, and 3. Cmax for bevacizumab in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. The bevacizumab pharmacokinetic parameters were normalized to 1 mg/kg dose.

Time frame:
Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) For Bevacizumab: Phase 1
ng/mLPhase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)
Cycle 1 Day 126460.05 (19574.60 to 35767.50)
Cycle 2 Day 126850.12 (19863.16 to 36294.76)
SecondaryMinimum Observed Plasma Trough Concentration (Cmin) For Bevacizumab: Phase 1
Time frame:
Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

No measurements were reported for this outcome.

SecondaryClearance (CL) For Bevacizumab: Phase 1

CL is a quantitative measure of the rate at which a drug substance is removed from the body. PK parameters of bevacizumab were combined for Cohorts 1, 2, and 3. CL for bevacizumab in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data.

Time frame:
Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Reported as:
Geometric mean · L/hr
Clearance (CL) For Bevacizumab: Phase 1
L/hrPhase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)
Cycle 1 Day 10.01 (0.01 to 0.02)
Cycle 2 Day 10.02 (0.01 to 0.02)
SecondaryPlasma Decay Half-Life (t1/2) For Bevacizumab: Phase 1

Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half. PK parameters of bevacizumab were combined for Cohorts 1, 2, and 3. t1/2 for bevacizumab in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data.

Time frame:
Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
Reported as:
Mean · hours
Plasma Decay Half-Life (t1/2) For Bevacizumab: Phase 1
hoursPhase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)
Cycle 1 Day 1205.97 ± 46.454
Cycle 2 Day 1210.22 ± 55.317
SecondaryDuration of Response (DR): Phase 2

Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response. CR: disappearance of all lesions and no appearance of new lesions. PR: \>=30% decrease in sum of LD of target lesions taking as reference the baseline sum LD, without progression of nontarget lesions and no appearance of new lesions. Progression: \>=20% increase in sum of LD of target lesions taking as references the smallest sum LD recorded since treatment start, unequivocal progression of existing nontarget lesions, or appearance of new lesions, occurrence of pleural effusion/ascites, substantiated by cytologic investigation.

Time frame:
Baseline (Phase 2) until disease progression, assessed every 6 weeks up to Week 148 (Phase 2) or follow-up (every 6 weeks after last dose of study drug until progression or start of alternate therapy)
Reported as:
Median · days
Duration of Response (DR): Phase 2
daysPhase 2: Axitinib + FOLFOXPhase 2: Bevacizumab + FOLFOXPhase 2: Axitinib + Bevacizumab + FOLFOX
Duration of Response (DR): Phase 2434.0 (246.0 to 666.0)NA (232.0 to NA)343.0 (168.0 to 490.0)
SecondaryProgression-Free Survival (PFS): Phase 2

Time in days from date of randomization to first documentation of objective tumor progression or death due to any cause. PFS was calculated as first event date minus the date of first dose of study medication plus 1. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death"). Progression: \>=20% increase in sum of LD of target lesions taking as references the smallest sum LD recorded since treatment start, unequivocal progression of existing nontarget lesions, or appearance of new lesions, occurrence of pleural effusion/ascites, substantiated by cytologic investigation.

Time frame:
Baseline (Phase 2) until disease progression, assessed every 6 weeks up to Week 148 (Phase 2) or follow-up (every 6 weeks after last dose of study drug until progression or start of alternate therapy)
Reported as:
Median · days
Progression-Free Survival (PFS): Phase 2
daysPhase 2: Axitinib + FOLFOXPhase 2: Bevacizumab + FOLFOXPhase 2: Axitinib + Bevacizumab + FOLFOX
Progression-Free Survival (PFS): Phase 2336 (225.0 to 749.0)485 (276.0 to NA)381 (238.0 to 425.0)
Statistical analysis
  • Phase 2: Axitinib + FOLFOX vs Phase 2: Bevacizumab + FOLFOX · Log Rank · p = 0.5699 · Hazard ratio (hr): 1.08 · 95% CI 0.47 to 2.45
  • Phase 2: Axitinib + FOLFOX vs Phase 2: Axitinib + Bevacizumab + FOLFOX · Log Rank · p = 0.2167 · Hazard ratio (hr): 0.73 · 95% CI 0.33 to 1.61
  • Phase 2: Bevacizumab + FOLFOX vs Phase 2: Axitinib + Bevacizumab + FOLFOX · Log Rank · p = 0.8746 · Hazard ratio (hr): 1.49 · 95% CI 0.75 to 2.98
SecondaryTime to Treatment Failure (TTF): Phase 2

TTF is defined as the time from the randomization to the date of the first documentation of PD, symptomatic deterioration, death due to any cause, or treatment discontinuation due to adverse event, refusal or other reasons. Progression: \>=20% increase in sum of LD of target lesions taking as references the smallest sum LD recorded since treatment start, unequivocal progression of existing nontarget lesions, or appearance of new lesions, occurrence of pleural effusion/ascites, substantiated by cytologic investigation.

Time frame:
Baseline (Phase 2) until disease progression, assessed every 6 weeks up to Week 148 (Phase 2) or follow-up (every 6 weeks after last dose of study drug until progression or start of alternate therapy)
Reported as:
Median · days
Time to Treatment Failure (TTF): Phase 2
daysPhase 2: Axitinib + FOLFOXPhase 2: Bevacizumab + FOLFOXPhase 2: Axitinib + Bevacizumab + FOLFOX
Time to Treatment Failure (TTF): Phase 2187.0 (162.0 to 315.0)241.0 (205.0 to 344.0)238.0 (155.0 to 333.0)
Statistical analysis
  • Phase 2: Axitinib + FOLFOX vs Phase 2: Bevacizumab + FOLFOX · Log Rank · p = 0.8884 · Hazard ratio (hr): 1.40 · 95% CI 0.81 to 2.41
  • Phase 2: Axitinib + FOLFOX vs Phase 2: Axitinib + Bevacizumab + FOLFOX · Log Rank · p = 0.6648 · Hazard ratio (hr): 1.12 · 95% CI 0.66 to 1.89
  • Phase 2: Bevacizumab + FOLFOX vs Phase 2: Axitinib + Bevacizumab + FOLFOX · Log Rank · p = 0.8065 · Hazard ratio (hr): 1.25 · 95% CI 0.75 to 2.07
SecondaryOverall Survival (OS): Phase 2

Time in days from randomization date to date of death due to any cause. OS was calculated as the death date minus the date of first dose of study medication plus 1. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).

Time frame:
Every 3 months after discontinuation of study treatment until death due to any cause or 1 year after randomization of the last participant
Reported as:
Median · days
Overall Survival (OS): Phase 2
daysPhase 2: Axitinib + FOLFOXPhase 2: Bevacizumab + FOLFOXPhase 2: Axitinib + Bevacizumab + FOLFOX
Overall Survival (OS): Phase 2552.0 (443.0 to 911.0)659.0 (493.0 to 899.0)601.0 (533.0 to 882.0)
Statistical analysis
  • Phase 2: Axitinib + FOLFOX vs Phase 2: Bevacizumab + FOLFOX · Log Rank · p = 0.6904 · Hazard ratio (hr): 1.155 · 95% CI 0.656 to 2.033
  • Phase 2: Axitinib + FOLFOX vs Phase 2: Axitinib + Bevacizumab + FOLFOX · Log Rank · p = 0.7364 · Hazard ratio (hr): 1.203 · 95% CI 0.676 to 2.141
  • Phase 2: Bevacizumab + FOLFOX vs Phase 2: Axitinib + Bevacizumab + FOLFOX · Log Rank · p = 0.4140 · Hazard ratio (hr): 0.941 · 95% CI 0.535 to 1.653
SecondaryChange From Baseline in M.D. Anderson Symptom Assessment Inventory - Diarrhea (MDASI-D) Symptom Severity and Interference Subscale Scores at Day 1 of Cycle 2 Through Day 1 Cycle 42 and Follow-up: Phase 2

PROs included assessment of symptom severity and interference which were measured using M.D. Anderson Symptom Assessment Inventory-Diarrhea (MDASI-D), 20-item questionnaire which assesses the severity of 14 symptoms over the past 24 hours, as well as symptoms interference with 6 areas of function (e.g., walking, work, mood), when the symptom was "at its worst". Each item is scored from 0 to 10, with '0' indicating that the symptom was either not present or did not interfere with their activities, and '10' indicating that the symptom was "as bad as you can imagine" or "interfered completely" with their life. The 2 subscales, symptom severity score and symptom interference score were average of respective items and ranged from 0 to 10, higher score indicating greater severity or interference of symptoms.

Time frame:
Cycle 1 Day 1 (baseline), every 2 weeks for the first 2 months (Cycle 2 Day 1 [C2D1], Cycle 3 Day 1, and Cycle 4 Day 1) then monthly thereafter starting Cycle 6 Day 1, and 28 days after the last dose
Reported as:
Mean · units on scale
Change From Baseline in M.D. Anderson Symptom Assessment Inventory - Diarrhea (MDASI-D) Symptom Severity and Interference Subscale Scores at Day 1 of Cycle 2 Through Day 1 Cycle 42 and Follow-up: Phase 2
units on scalePhase 2: Axitinib + FOLFOXPhase 2: Bevacizumab + FOLFOXPhase 2: Axitinib + Bevacizumab + FOLFOX
Severity Scale: Baseline (n=41,43,40)1.62 ± 1.572.20 ± 1.932.18 ± 2.06
Severity Scale: C2D1 (n=37,37,37)0.63 ± 1.220.04 ± 1.160.80 ± 1.32
Severity Scale: C3D1 (n=32,38,32)0.68 ± 1.29-0.22 ± 1.170.63 ± 1.61
Severity Scale: C4D1 (n=23,37,30)0.88 ± 1.41-0.40 ± 1.270.64 ± 1.68
Severity Scale: C5D1 (n=23,34,29)0.72 ± 1.37-0.34 ± 1.590.60 ± 2.13
Severity Scale: C6D1 (n=15,38,26)0.70 ± 1.800.09 ± 1.440.96 ± 1.60
Severity Scale: C7D1 (n=12,30,22)0.28 ± 1.51-0.16 ± 1.550.26 ± 1.22
Severity Scale: C8D1 (n=17,29,22)0.28 ± 1.45-0.13 ± 1.560.42 ± 1.74
Severity Scale: C9D1 (n=11,24,21)-0.15 ± 1.55-0.03 ± 1.670.76 ± 1.50
Severity Scale: C10D1 (n=14,27,21)0.28 ± 1.370.06 ± 1.520.77 ± 1.52
Severity Scale: C11D1 (n=10,20,19)0.15 ± 1.57-0.05 ± 1.590.57 ± 1.33
Severity Scale: C12D1 (n=11,23,16)0.32 ± 1.400.47 ± 1.370.38 ± 1.14
Severity Scale: C13D1 (n=8,13,12)-0.09 ± 1.430.10 ± 1.350.73 ± 1.55
Severity Scale: C14D1 (n=8,17,14)0.03 ± 0.810.38 ± 1.48-0.05 ± 1.44
Severity Scale: C15D1 (n=7,11,9)0.28 ± 1.500.42 ± 1.490.71 ± 1.34
Severity Scale: C16D1 (n=7,17,14)-0.30 ± 0.880.11 ± 1.460.05 ± 2.08
Severity Scale: C17D1 (n=5,11,6)-0.20 ± 0.700.21 ± 1.690.72 ± 1.07
Severity Scale: C18D1 (n=6,14,9)0.02 ± 0.850.31 ± 1.150.61 ± 1.55
Severity Scale: C19D1 (n=4,8,16)-0.18 ± 0.540.34 ± 1.420.81 ± 2.32
Severity Scale: C20D1 (n=5,14,8)-0.06 ± 0.540.15 ± 1.21-0.06 ± 1.67
Severity Scale: C21D1 (n=4,5,5)-0.25 ± 0.710.27 ± 1.901.20 ± 1.35
Severity Scale: C22D1 (n=3,11,8)0.57 ± 0.450.81 ± 0.950.09 ± 1.37
Severity Scale: C23D1 (n=4,5,3)0.30 ± 0.800.64 ± 1.321.05 ± 1.11
Severity Scale: C24D1 (n=5,11,7)0.91 ± 2.070.37 ± 1.10-0.20 ± 1.62
Severity Scale: C25D1 (n=4,5,5)0.25 ± 0.96-0.03 ± 1.12-0.30 ± 1.63
Severity Scale: C26D1 (n=4,6,7)-0.05 ± 0.760.46 ± 0.72-0.13 ± 1.79
Severity Scale: C27D1 (n=4,3,4)-0.21 ± 0.650.07 ± 0.990.34 ± 2.70
Severity Scale: C28D1 (n=4,5,7)0.12 ± 0.820.74 ± 1.01-0.43 ± 2.00
Severity Scale: C29D1 (n=2,3,4)3.00 ± 2.12-0.14 ± 0.58-0.09 ± 2.51
Severity Scale: C30D1 (n=3,6,3)1.05 ± 1.700.45 ± 1.050.64 ± 0.68
Severity Scale: C31D1 (n=1,1,3)-0.50 ± NA-0.64 ± NA1.55 ± 1.69
Severity Scale: C32D1 (n=2,4,4)0.11 ± 0.250.80 ± 0.931.29 ± 1.03
Severity Scale: C33D1 (n=0,0,2)NA ± NANA ± NA0.89 ± 1.26
Severity Scale: C34D1 (n=2,4,3)0.04 ± 0.150.75 ± 0.890.43 ± 0.74
Severity Scale: C35D1 (n=0,0,1)NA ± NANA ± NA0.79 ± NA
Severity Scale: C36D1 (n=2,3,2)0.29 ± 0.511.24 ± 1.22-0.18 ± 0.25
Severity Scale: C37D1 (n=0,1,0)NA ± NA0.86 ± NANA ± NA
Severity Scale: C38D1 (n=2,2,1)0.13 ± 0.281.68 ± 1.970.86 ± NA
Severity Scale: C39D1 (n=0,1,0)NA ± NA0.86 ± NANA ± NA
Severity Scale: C40D1 (n=2,2,2)0.18 ± 0.351.29 ± 1.110.43 ± 0.61
Severity Scale: C42D1 (n=2,2,1)0.18 ± 0.351.25 ± 1.260.00 ± NA
Severity Scale: Follow_Up (n=4,15,14)1.29 ± 2.75-0.00 ± 1.660.29 ± 1.72
Interference Scale: Baseline (n=41,43,40)2.50 ± 2.702.79 ± 2.572.47 ± 2.66
Interference Scale: C2D1 (n=37,37,36)0.46 ± 1.80-0.08 ± 1.740.78 ± 2.55
Interference Scale: C3D1 (n=31,38,30)0.60 ± 2.37-0.57 ± 1.881.09 ± 2.37
Interference Scale: C4D1 (n=23,36,30)0.92 ± 2.16-0.54 ± 1.891.15 ± 2.37
Interference Scale: C5D1 (n=23,34,29)0.65 ± 2.20-0.59 ± 1.981.19 ± 2.90
Interference Scale: C6D1 (n=15,38,26)0.32 ± 2.01-0.18 ± 2.330.99 ± 2.54
Interference Scale: C7D1 (n=12,30,22)0.43 ± 1.25-0.59 ± 2.130.55 ± 2.05
Interference Scale: C8D1 (n=17,29,22)0.01 ± 1.58-0.10 ± 2.000.48 ± 1.87
Interference Scale: C9D1 (n=11,24,21)-0.14 ± 1.08-0.39 ± 2.310.75 ± 1.76
Interference Scale: C10D1 (n=14,27,21)-0.18 ± 1.800.15 ± 2.060.99 ± 2.12
Interference Scale: C11D1 (n=10,20,19)0.42 ± 1.23-0.51 ± 1.750.84 ± 2.50
Interference Scale: C12D1 (n=10,23,16)0.03 ± 0.780.17 ± 2.230.38 ± 1.51
Interference Scale: C13D1 (n=8,13,12)-0.50 ± 1.56-0.31 ± 2.490.31 ± 1.70
Interference Scale: C14D1 (n=8,17,14)-0.10 ± 0.840.15 ± 2.570.29 ± 2.12
Interference Scale: C15D1 (n=7,11,9)-0.52 ± 0.850.27 ± 1.910.70 ± 2.36
Interference Scale: C16D1 (n=7,17,14)-0.02 ± 0.33-0.48 ± 2.31-0.01 ± 2.38
Interference Scale: C17D1 (n=5,11,6)-0.90 ± 1.31-0.29 ± 3.161.17 ± 1.28
Interference Scale: C18D1 (n=6,14,9)0.06 ± 0.340.04 ± 2.381.00 ± 2.26
Interference Scale: C19D1 (n=4,8,6)0.04 ± 0.340.54 ± 2.251.04 ± 1.84
Interference Scale: C20D1 (n=5,14,8)0.27 ± 0.65-0.08 ± 2.340.35 ± 2.07
Interference Scale: C21D1 (n=4,5,5)-0.04 ± 0.86-0.97 ± 3.501.83 ± 1.28
Interference Scale: C22D1 (n=3,11,8)0.44 ± 0.840.74 ± 1.710.83 ± 2.05
Interference Scale: C23D1 (n=4,5,3)0.21 ± 0.421.13 ± 2.581.28 ± 1.80
Interference Scale: C24D1 (n=5,11,7)2.00 ± 3.250.30 ± 2.650.55 ± 2.33
Interference Scale: C25D1 (n=4,5,5)0.00 ± 0.410.10 ± 2.450.90 ± 0.88
Interference Scale: C26D1 (n=4,6,7)0.33 ± 0.850.67 ± 1.800.33 ± 2.11
Interference Scale: C27D1 (n=4,3,4)0.04 ± 0.520.11 ± 1.131.63 ± 2.44
Interference Scale: C28D1 (n=4,5,7)0.71 ± 1.190.97 ± 1.810.19 ± 2.40
Interference Scale: C29D1 (n=2,3,4)3.25 ± 3.89-0.56 ± 0.961.33 ± 2.97
Interference Scale: C30D1 (n=3,6,3)0.94 ± 1.491.08 ± 2.161.06 ± 1.83
Interference Scale: C31D1 (n=1,1,3)0.00 ± NA-0.17 ± NA2.33 ± 2.08
Interference Scale: C32D1 (n=2,4,4)0.08 ± 0.121.50 ± 2.262.17 ± 1.81
Interference Scale: C33D1 (n=0,0,2)NA ± NANA ± NA1.92 ± 2.71
Interference Scale: C34D1 (n=2,4,3)0.17 ± 0.241.25 ± 1.891.11 ± 1.51
Interference Scale: C35D1 (n=0,0,1)NA ± NANA ± NA1.67 ± NA
Interference Scale: C36D1 (n=2,3,2)0.17 ± 0.241.89 ± 2.181.33 ± 1.89
Interference Scale: C37D1 (n=0,1,0)NA ± NA0.83 ± NANA ± NA
Interference Scale: C38D1 (n=2,2,1)0.08 ± 0.122.25 ± 2.47-0.17 ± NA
Interference Scale: C39D1 (n=0,1,0)NA ± NA0.50 ± NANA ± NA
Interference Scale: C40D1 (n=2,2,2)0.42 ± 0.592.50 ± 2.120.25 ± 0.35
Interference Scale: C42D1 (n=2,2,1)0.25 ± 0.352.58 ± 2.240.00 ± NA
Interference Scale: Follow Up (n=4,15,14)1.33 ± 2.48-0.21 ± 2.440.91 ± 1.65

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1: Axitinib + FOLFOX + Bevacizumab (Cohort 1)—3/6 (50%)6/6 (100%)
Phase 1: Axitinib + FOLFOX + Bevacizumab (Cohort 2)—2/6 (33.3%)6/6 (100%)
Phase 1: Axitinib + FOLFOX + Bevacizumab (Cohort 3)—2/4 (50%)4/4 (100%)
Phase 1: Axitinib + FOLFIRI (Cohort 4)—3/8 (37.5%)8/8 (100%)
Phase 1: Axitinib + FOLFOX (Cohort 5)—5/6 (83.3%)6/6 (100%)
Phase 1: Axitinib + FOLFIRI (Cohort 6)—1/4 (25%)4/4 (100%)
Phase 1: Axitinib + FOLFOX (Cohort 7)—1/6 (16.7%)6/6 (100%)
Phase 1: Axitinib + FOLFIRI (Cohort 8)—1/3 (33.3%)3/3 (100%)
Phase 1: Axitinib + FOLFOX (Cohort 9)—8/18 (44.4%)18/18 (100%)
Phase 2: Axitinib + FOLFOX—15/39 (38.5%)39/39 (100%)
Phase 2: Bevacizumab + FOLFOX—17/43 (39.5%)42/43 (97.7%)
Phase 2: Axitinib + Bevacizumab + FOLFOX—23/41 (56.1%)39/41 (95.1%)
Most frequent serious events
Showing 10 of 105
Most frequent serious events
EventPhase 1: Axitinib + FOLFOX + Bevacizumab (Cohort 1)Phase 1: Axitinib + FOLFOX + Bevacizumab (Cohort 2)Phase 1: Axitinib + FOLFOX + Bevacizumab (Cohort 3)Phase 1: Axitinib + FOLFIRI (Cohort 4)Phase 1: Axitinib + FOLFOX (Cohort 5)Phase 1: Axitinib + FOLFIRI (Cohort 6)Phase 1: Axitinib + FOLFOX (Cohort 7)Phase 1: Axitinib + FOLFIRI (Cohort 8)Phase 1: Axitinib + FOLFOX (Cohort 9)Phase 2: Axitinib + FOLFOXPhase 2: Bevacizumab + FOLFOXPhase 2: Axitinib + Bevacizumab + FOLFOX
Staphylococcal infectionInfections and infestations0/60/60/40/80/60/40/61/31/181/390/430/41
DehydrationMetabolism and nutrition disorders0/62/60/40/82/60/40/60/30/183/392/437/41
Diverticular perforationGastrointestinal disorders0/60/61/40/80/60/40/60/30/180/390/430/41
Chest painGeneral disorders0/60/61/40/80/60/40/60/30/180/391/432/41
CholecystitisHepatobiliary disorders0/60/60/40/81/61/40/60/30/180/390/430/41
CholelithiasisHepatobiliary disorders0/60/60/40/80/61/40/60/30/180/390/430/41
Abscess intestinalInfections and infestations0/60/61/40/80/60/40/60/30/180/390/430/41
Deep vein thrombosisVascular disorders0/60/61/40/81/60/40/60/30/182/391/432/41
NeutropeniaBlood and lymphatic system disorders0/61/60/40/80/60/40/60/30/180/390/430/41
BradycardiaCardiac disorders1/60/60/40/80/60/40/60/30/181/390/430/41
Most frequent other events
Showing 10 of 310
Most frequent other events
EventPhase 1: Axitinib + FOLFOX + Bevacizumab (Cohort 1)Phase 1: Axitinib + FOLFOX + Bevacizumab (Cohort 2)Phase 1: Axitinib + FOLFOX + Bevacizumab (Cohort 3)Phase 1: Axitinib + FOLFIRI (Cohort 4)Phase 1: Axitinib + FOLFOX (Cohort 5)Phase 1: Axitinib + FOLFIRI (Cohort 6)Phase 1: Axitinib + FOLFOX (Cohort 7)Phase 1: Axitinib + FOLFIRI (Cohort 8)Phase 1: Axitinib + FOLFOX (Cohort 9)Phase 2: Axitinib + FOLFOXPhase 2: Bevacizumab + FOLFOXPhase 2: Axitinib + Bevacizumab + FOLFOX
NauseaGastrointestinal disorders6/64/63/45/85/63/45/63/313/1822/3923/4323/41
VomitingGastrointestinal disorders3/63/61/45/80/61/42/63/36/1812/3912/4315/41
FatigueGeneral disorders5/64/64/44/83/64/44/62/314/1824/3929/4331/41
Mucosal inflammationGeneral disorders6/62/61/42/84/62/41/61/36/187/399/4315/41
Back painMusculoskeletal and connective tissue disorders2/61/60/40/81/61/41/63/34/186/393/436/41
Neuropathy peripheralNervous system disorders3/62/64/40/82/60/44/60/35/1812/3923/4317/41
HypertensionVascular disorders6/63/64/42/82/62/42/62/38/1816/398/4326/41
Decreased appetiteMetabolism and nutrition disorders5/64/62/44/84/60/43/61/35/1810/3910/4320/41
DehydrationMetabolism and nutrition disorders5/60/60/44/83/60/41/61/33/187/398/4312/41
AnaemiaBlood and lymphatic system disorders2/60/62/41/82/63/41/61/35/189/399/4312/41

Baseline characteristics

Age, Customized
Age, Customized(Participants)Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1)Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 2)Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 3)Phase 1: Axitinib + FOLFIRI (Cohort 4)Phase 1: Axitinib + FOLFOX (Cohort 5)Phase 1: Axitinib + FOLFIRI (Cohort 6)Phase 1: Axitinib + FOLFOX (Cohort 7)Phase 1: Axitinib + FOLFIRI (Cohort 8)Phase 1: Axitinib + FOLFIRI (Cohort 9)Phase 2: Axitinib + FOLFOXPhase 2: Bevacizumab + FOLFOXPhase 2: Axitinib + Bevacizumab + FOLFOXTotal
Less than (<) 18 years0000000000000
18 to 44 years12011100124821
45 to 64 years213321531322182396
Greater than or equal to (>=) 65 years33143210418211070
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1)Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 2)Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 3)Phase 1: Axitinib + FOLFIRI (Cohort 4)Phase 1: Axitinib + FOLFOX (Cohort 5)Phase 1: Axitinib + FOLFIRI (Cohort 6)Phase 1: Axitinib + FOLFOX (Cohort 7)Phase 1: Axitinib + FOLFIRI (Cohort 8)Phase 1: Axitinib + FOLFIRI (Cohort 9)Phase 2: Axitinib + FOLFOXPhase 2: Bevacizumab + FOLFOXPhase 2: Axitinib + Bevacizumab + FOLFOXTotal
Female31221220717151567
Male3526524311252826120
08

Study locations

107 sites
  • Pfizer Investigational Site
    Daphne, Alabama 36526, United States
  • Pfizer Investigational Site
    Huntsville, Alabama 35801, United States
  • Pfizer Investigational Site
    Huntsville, Alabama 35805, United States
  • Pfizer Investigational Site
    Mobile, Alabama 36608, United States
  • Pfizer Investigational Site
    Antioch, California 94531, United States
  • Pfizer Investigational Site
    Colton, California 92324, United States
  • Pfizer Investigational Site
    Corona, California 92879, United States
  • Pfizer Investigational Site
    Gilroy, California 95020, United States
  • Pfizer Investigational Site
    Glendora, California 91741, United States
  • Pfizer Investigational Site
    La Jolla, California 92037, United States
  • Pfizer Investigational Site
    La Jolla, California 92093, United States
  • Pfizer Investigational Site
    LaJolla, California 92093, United States
  • Pfizer Investigational Site
    Pasadena, California 91105, United States
  • Pfizer Investigational Site
    Pleasant Hill, California 94523, United States
  • Pfizer Investigational Site
    Pomona, California 91767, United States
  • Pfizer Investigational Site
    Rancho Cucamonga, California 91730, United States
  • Pfizer Investigational Site
    Rancho Mirage, California 92270, United States
  • Pfizer Investigational Site
    Redlands, California 92374, United States
  • Pfizer Investigational Site
    San Diego, California 92103, United States
  • Pfizer Investigational Site
    San Diego, California 92121, United States
  • Pfizer Investigational Site
    San Leandro, California 94578, United States
  • Pfizer Investigational Site
    West Covina, California 91790, United States
  • Pfizer Investigational Site
    Auroa, Colorado 80012, United States
  • Pfizer Investigational Site
    Boulder, Colorado 80303, United States
  • Pfizer Investigational Site
    Colorado Springs, Colorado 80909, United States
  • Pfizer Investigational Site
    Denver, Colorado 80218, United States
  • Pfizer Investigational Site
    Denver, Colorado 80220, United States
  • Pfizer Investigational Site
    Lakewood, Colorado 80228, United States
  • Pfizer Investigational Site
    Littleton, Colorado 80120-4413, United States
  • Pfizer Investigational Site
    Lone Tree, Colorado 80124, United States
  • Pfizer Investigational Site
    Longmont, Colorado 80501, United States
  • Pfizer Investigational Site
    Parker, Colorado 80138, United States
  • Pfizer Investigational Site
    Thornton, Colorado 80260, United States
  • Pfizer Investigational Site
    Ocala, Florida 34471, United States
  • Pfizer Investigational Site
    Stuart, Florida 34994, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30318, United States
  • Pfizer Investigational Site
    Beech Grove, Indiana 46107, United States
  • Pfizer Investigational Site
    Indianapolis, Indiana 46237, United States
  • Pfizer Investigational Site
    Jeffersonville, Indiana 47130, United States
  • Pfizer Investigational Site
    Muncie, Indiana 47303, United States
  • Pfizer Investigational Site
    Kansas City, Kansas 66112, United States
  • Pfizer Investigational Site
    Overland Park, Kansas 66210, United States
  • Pfizer Investigational Site
    Louisville, Kentucky 40202, United States
  • Pfizer Investigational Site
    Louisville, Kentucky 40207, United States
  • Pfizer Investigational Site
    Louisville, Kentucky 40217, United States
  • Pfizer Investigational Site
    Louisville, Kentucky 40241, United States
  • Pfizer Investigational Site
    Shelbyville, Kentucky 40065, United States
  • Pfizer Investigational Site
    Baton Rouge, Louisiana 70809, United States
  • Pfizer Investigational Site
    Brownstone, Michigan 48183, United States
  • Pfizer Investigational Site
    Dearborn, Michigan 48126, United States
  • Pfizer Investigational Site
    Detroit, Michigan 48202, United States
  • Pfizer Investigational Site
    West Bloomfield, Michigan 48322, United States
  • Pfizer Investigational Site
    Kansas City, Missouri 64111, United States
  • Pfizer Investigational Site
    Kansas City, Missouri 64131, United States
  • Pfizer Investigational Site
    Kansas City, Missouri 64154, United States
  • Pfizer Investigational Site
    Lee's Summit, Missouri 64064, United States
  • Pfizer Investigational Site
    St. Louis, Missouri 63110, United States
  • Pfizer Investigational Site
    Grand Island, Nebraska 68803, United States
  • Pfizer Investigational Site
    Las Vegas, Nevada 89135, United States
  • Pfizer Investigational Site
    Summit, New Jersey 07902, United States
  • Pfizer Investigational Site
    Albany, New York 12206, United States
  • Pfizer Investigational Site
    Albany, New York 12208, United States
  • Pfizer Investigational Site
    Amsterdam, New York 12010, United States
  • Pfizer Investigational Site
    Hudson, New York 12534, United States
  • Pfizer Investigational Site
    Latham, New York 12110-0610, United States
  • Pfizer Investigational Site
    Rexford, New York 12148, United States
  • Pfizer Investigational Site
    Troy, New York 12180, United States
  • Pfizer Investigational Site
    Kernersville, North Carolina 27284, United States
  • Pfizer Investigational Site
    Lexington, North Carolina 27295, United States
  • Pfizer Investigational Site
    Mount Airy, North Carolina 27030, United States
  • Pfizer Investigational Site
    North Wilkesboro, North Carolina 28659, United States
  • Pfizer Investigational Site
    Pollocksville, North Carolina 28573, United States
  • Pfizer Investigational Site
    Winston Salem, North Carolina 27103, United States
  • Pfizer Investigational Site
    Oregon City, Oregon 97045, United States
  • Pfizer Investigational Site
    Portland, Oregon 97213, United States
  • Pfizer Investigational Site
    Portland, Oregon 97225, United States
  • Pfizer Investigational Site
    Portland, Oregon 97227, United States
  • Pfizer Investigational Site
    Tualatin, Oregon 97062, United States
  • Pfizer Investigational Site
    West Reading, Pennsylvania 19611, United States
  • Pfizer Investigational Site
    Charleston, South Carolina 29406, United States
  • Pfizer Investigational Site
    Easley, South Carolina 29640, United States
  • Pfizer Investigational Site
    Greenville, South Carolina 29605, United States
  • Pfizer Investigational Site
    Greenville, South Carolina 29615, United States
  • Pfizer Investigational Site
    Seneca, South Carolina 29672, United States
  • Pfizer Investigational Site
    Spartanburg, South Carolina 29307, United States
  • Pfizer Investigational Site
    Chattanooga, Tennessee 37403, United States
  • Pfizer Investigational Site
    Franklin, Tennessee 37067, United States
  • Pfizer Investigational Site
    Gallatin, Tennessee 37066, United States
  • Pfizer Investigational Site
    Hermitage, Tennessee 37076, United States
  • Pfizer Investigational Site
    Lebanon, Tennessee 37087, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37203, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37205, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37207, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37211, United States
  • Pfizer Investigational Site
    Smyrna, Tennessee 37167, United States
  • Pfizer Investigational Site
    Dallas, Texas 75235, United States
  • Pfizer Investigational Site
    Dallas, Texas 75237, United States
  • Pfizer Investigational Site
    Dallas, Texas 75246, United States
  • Pfizer Investigational Site
    Dallas, Texas 75390, United States
  • Pfizer Investigational Site
    Fort Worth, Texas 76177, United States

Showing the first 100 of 107 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Hoh CK, Burris HA 3rd, Bendell JC, Tarazi J, Rosbrook B, Kim S, Infante JR, Reid TR. Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours. Br J Cancer. 2014 Feb 18;110(4):875-81. doi: 10.1038/bjc.2013.806. Epub 2014 Jan 14. PubMed 24423921 ↗
  • Infante JR, Reid TR, Cohn AL, Edenfield WJ, Cescon TP, Hamm JT, Malik IA, Rado TA, McGee PJ, Richards DA, Tarazi J, Rosbrook B, Kim S, Cartwright TH. Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study. Cancer. 2013 Jul 15;119(14):2555-63. doi: 10.1002/cncr.28112. Epub 2013 Apr 19. PubMed 23605883 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2006, a primary completion of Apr 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2007
First posted
Apr 16, 2007
Start
Jan 2006
Primary completionActual
Apr 2012
CompletionActual
Nov 2012
Results first posted
Jun 4, 2013
Last update
Dec 6, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00460603
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 16, 2007
Start date
Jan 2006
Primary completion
Apr 2012
Completion
Nov 2012
Results posted
Jun 4, 2013
Last update
Dec 6, 2013

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axitinib

Start the discussion